Story
Psychedelic Stocks Rally After Eli Lilly Announces $2.8 Billion AtaiBeckley Acquisition
Summary
Shares of psychedelic drug developers surged after pharmaceutical giant Eli Lilly announced a definitive agreement to acquire AtaiBeckley, a deal seen as a major validation for the emerging sector.
Shares of companies developing psychedelic-based therapies surged in premarket trading Thursday after Eli Lilly announced it would acquire AtaiBeckley Inc. in a deal valued at up to $3.8 billion. The acquisition sent a wave of optimism through the sector, signaling significant interest from established pharmaceutical players.
The Acquisition Details
Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, according to the announcement. The deal also includes a Contingent Value Right (CVR) of up to an additional $2.50 per share, tied to specific development and regulatory milestones for AtaiBeckley's main drug candidates, BPL-003 and VLS-01.
The upfront cash payment represents an aggregate equity value of approximately $2.8 billion. The CVR could provide an additional $1.0 billion in value to shareholders. The transaction is expected to close in the third quarter.
Market Impact and Sector-Wide Lift
The news triggered a significant rally among publicly traded psychedelic medicine companies. As of Thursday's premarket session:
Ad- AtaiBeckley shares soared 30.8%.
- GH Research (GHRS) jumped 18.9%.
- Compass Pathways (CMPS) rose 7.4%.
Analysts view Lilly's move as a validation of the therapeutic potential and commercial viability of the psychedelic drug class, particularly for treating mental health conditions like treatment-resistant depression.
Analyst Perspective
In a note to clients, RBC Capital stated the deal has a "direct and compelling read-through" for GH Research. Analyst Brian Abrahams highlighted that GH Research's lead asset, GH001, shares a nearly identical mechanism with AtaiBeckley’s BPL-003. Both are based on 5-MeO-DMT and target treatment-resistant depression.
RBC Capital suggested that Lilly's willingness to pay a premium for AtaiBeckley "would set a floor for GHRS shares" and positions the company as an attractive target for other strategic acquirers. The firm maintained its Outperform rating on GH Research with a $40 price target, citing the deal's positive implications for the space's scalability and regulatory outlook.
Read next
More on Stocks
CIBC Offers Compelling Value Profile Among Major Canadian Banks
While TD Bank trades at the lowest price-to-earnings multiple, an analysis of yield and upside potential positions Canadian Imperial Bank of Commerce (CIBC) as a more balanced value investment among its peers.
Volvo Cars Appoints Klaus Zellmer as Next CEO to Succeed Hakan Samuelsson
Volvo Cars has named Klaus Zellmer as its next president and chief executive officer, replacing the departing Hakan Samuelsson. The transition comes as the automaker pursues an aggressive growth strategy amid market challenges.
Analyst 'Strong Buy' Ratings Signal Upside for TSX-Listed Miners
Several Canadian gold and copper miners, including Equinox Gold and Kinross Gold, are attracting strong buy ratings from analysts who project double-digit upside potential based on recent company-specific catalysts.
Saudi Tadawul All Share Index Slips to 1-Month Low on Broad Sector Declines
Saudi Arabia's benchmark stock index, the Tadawul All Share, closed down 0.26% on Sunday to reach its lowest point in a month, dragged lower by weakness in the insurance and energy sectors.